Iliac Stents Market Size & Growth Forecast 2027–2036, By Segments (Type, End-use, Artery Lesions), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Iliac Stents Market size was worth USD 1.07 Billion in 2026 and is expected to grow at 5.08% CAGR between 2027 and 2036, surpassing USD 1.76 Billion by 2036. The industry revenue for 2027 is assessed at USD 1.12 Billion.
Get more details on this report
Request Free Sample ReportIliac Stents Market Intelligence Snapshot
Regional Market Dynamics
- North America held 46.32% of the market in 2026, supported by advanced vascular care infrastructure, specialized cardiovascular centers, reimbursement frameworks, and established minimally invasive treatment adoption.
- Asia Pacific growth is supported by rising vascular disorders, population aging, expanding healthcare infrastructure, greater specialist availability, hospital investment, and increasing awareness of peripheral vascular disease.
Segment Momentum
- Balloon-expandable stents lead the market because they provide precise placement and controlled deployment, making them well suited for iliac artery procedures where accurate positioning is essential.
- Ambulatory surgical centers are expanding rapidly as more minimally invasive iliac artery procedures shift to outpatient settings that offer efficient treatment pathways, shorter recovery times, and cost-effective patient care.
Market Expansion Drivers
- Rising peripheral artery disease prevalence driving demand for minimally invasive vascular interventions
- Advancements in stent materials and design improving procedural success and patient outcomes
- Growing preference for outpatient endovascular procedures expanding hospital adoption of stent therapies
Leading Market Participants
- Leading companies in the iliac stents market include Abbott Laboratories (United States), Medtronic plc (Ireland), Boston Scientific Corporation (United States), Becton, Dickinson and Company (United States), B. Braun Melsungen AG (Germany), Biotronik SE & Co. KG (Germany), Cook Medical LLC (United States), W. L. Gore & Associates, Inc. (United States), Cordis (United States), iVascular S.L.U. (Spain)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.07 Billion
- 2027 Estimated Market Size: USD 1.12 Billion
- Projected Market Size: USD 1.76 Billion by 2036
- Growth Forecast: 5.08% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Balloon-expandable Stents (Type) | Hospitals (End-use) | Common Iliac Artery Lesions (Artery Lesions)
- Emerging Opportunity Segment: Covered Stents (Type) | Ambulatory Surgical Centers (End-use) | Complete Obstructive Lesions (Artery Lesions)
Market Growth Drivers and Industry Trends
Rising peripheral artery disease prevalence driving demand for minimally invasive vascular interventions
The growing incidence of peripheral artery disease, fueled by lifestyle-related risk factors and an aging population, is increasing the need for effective vascular treatment options. The iliac stents market growth is driven by the rising preference for minimally invasive interventions that restore blood flow while reducing procedural risks compared with conventional open surgery. Healthcare providers are increasingly recommending endovascular therapies for patients experiencing iliac artery blockages due to their ability to shorten recovery times, minimize hospital stays, and improve procedural efficiency. Greater awareness of early diagnosis and timely treatment has also encouraged broader utilization of vascular intervention procedures across specialized cardiovascular care settings.
Advancements in stent materials and design improving procedural success and patient outcomes
Continuous innovation in stent engineering has significantly enhanced the safety, durability, and clinical performance of vascular implants used in iliac artery interventions. Advances in material science and device architecture will propel the iliac stents market growth by enabling products with greater flexibility, improved radial strength, and enhanced adaptability to complex vascular anatomies. Modern stent designs are engineered to optimize vessel support while reducing the likelihood of restenosis and procedural complications, allowing clinicians to achieve more precise placement and long-term vessel patency. Improvements in delivery systems further contribute to procedural accuracy and expand the suitability of endovascular treatment across diverse patient populations.
Growing preference for outpatient endovascular procedures expanding hospital adoption of stent therapies
Healthcare systems are increasingly shifting suitable vascular interventions toward outpatient settings to improve resource utilization and enhance patient convenience. This evolving treatment model will boost the iliac stents market demand as hospitals and ambulatory care centers expand their adoption of endovascular stent therapies that require less invasive techniques and streamlined post-procedure care. Advances in imaging guidance, catheter technologies, and procedural protocols have made outpatient treatment a practical option for many patients, enabling healthcare providers to deliver efficient vascular care while optimizing clinical workflows and reducing the burden on inpatient facilities.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising peripheral artery disease prevalence driving demand for minimally invasive vascular interventions | 2% | High | North America, Europe | High | Near Term |
| Advancements in stent materials and design improving procedural success and patient outcomes | 1.8% | High | North America, Asia Pacific | High | Mid Term |
| Growing preference for outpatient endovascular procedures expanding hospital adoption of stent therapies | 1.5% | Moderate | Global | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
Holding the largest share of the iliac stents market, North America accounted for 46.32% in 2026, reflecting the region's well-developed vascular care infrastructure and strong utilization of minimally invasive endovascular procedures. High awareness of peripheral artery disease, access to specialized cardiovascular centers, and established reimbursement frameworks support the adoption of iliac stenting procedures. Continued improvements in stent design, delivery systems, and image-guided interventions are also strengthening the role of endovascular treatment among patients requiring vascular revascularization.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is projected to experience the fastest growth as the prevalence of vascular disorders rises alongside population aging, urbanization, and changing lifestyle patterns. Healthcare infrastructure is expanding across major economies, while greater availability of interventional cardiology and vascular specialists is improving access to minimally invasive therapies. Increasing investment in advanced hospital facilities and growing awareness of peripheral vascular disease are further supporting the adoption of iliac stents across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
United States 🇺🇸
Advanced Endovascular CareThe U.S. market prioritizes minimally invasive treatment approaches for peripheral artery disease using advanced iliac stent technologies. Healthcare providers across the U.S. increasingly adopt devices designed for procedural precision, long-term vessel support, and complex anatomical conditions.
Germany 🇩🇪
Evidence-Driven AdoptionGermany emphasizes clinically validated iliac stents that align with standardized vascular treatment practices. Hospitals in Germany increasingly evaluate product durability, procedural efficiency, and compatibility with advanced endovascular interventions when selecting stent technologies.
Japan 🇯🇵
Aging Care SolutionsJapan's aging population supports continued demand for iliac stents used in managing peripheral vascular disease. Japanese healthcare providers prioritize minimally invasive devices that facilitate reliable outcomes while supporting efficient recovery for elderly patient populations.
South Korea 🇰🇷
Minimally Invasive ExpansionSouth Korea continues expanding the use of endovascular procedures across specialized vascular care centers. Demand in South Korea favors iliac stents that improve procedural flexibility, imaging visibility, and treatment efficiency for complex vascular interventions.
France 🇫🇷
Hospital Treatment OptimizationFrance focuses on improving vascular treatment pathways through wider adoption of advanced endovascular devices. Healthcare institutions in France seek iliac stents that support consistent clinical performance while fitting established interventional radiology and vascular surgery practices.
Italy 🇮🇹
Peripheral Care ModernizationItaly is strengthening peripheral vascular treatment capabilities through continued investment in minimally invasive technologies. Clinicians across Italy favor iliac stents that simplify deployment while addressing diverse lesion characteristics encountered in routine clinical practice.
Segment Leadership and Growth Trends
Iliac Stents Market Share (%), by Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType Segment Analysis: Balloon-expandable Stents (Largest Segment) vs Covered Stents (Fastest-Growing Segment)
The balloon-expandable stents segment held the largest share in 2026, reflecting their widespread use in procedures requiring accurate stent placement and controlled deployment within the iliac arteries. These stents provide physicians with enhanced precision during intervention, making them particularly suitable for treating lesions where exact positioning is critical. Their established clinical adoption and consistent procedural performance continue to support the segment’s leading position.
In the iliac stents market, the covered stents segment is emerging as the fastest-growing category due to increasing demand for devices capable of managing more complex vascular conditions while providing an additional protective barrier within the treated vessel. Their ability to support vessel integrity and address challenging lesion characteristics has encouraged broader clinical adoption. Ongoing advancements in stent design and expanding use in complex endovascular procedures are expected to sustain the segment’s rapid growth.
End-use Segment Analysis: Hospitals (Largest Segment) vs Ambulatory Surgical Centers (Fastest-Growing Segment)
The hospitals segment represented the largest end-use category in 2026, supported by the availability of specialized vascular care teams, advanced imaging infrastructure, and comprehensive perioperative services required for iliac artery interventions. Hospitals remain the primary setting for complex endovascular procedures due to their ability to manage patients with multiple comorbidities and provide immediate access to multidisciplinary clinical expertise. These advantages continue to reinforce their dominant role within the market.
Ambulatory surgical centers are emerging as the fastest-growing end-use segment in the iliac stents market as healthcare systems increasingly shift suitable minimally invasive vascular procedures toward outpatient settings. These facilities offer efficient treatment pathways, shorter recovery times, and streamlined patient management while maintaining high standards of procedural care. Growing preference for cost-effective outpatient interventions is contributing to the expansion of this segment.
Artery Lesions Segment Analysis: Common Iliac Artery Lesions (Largest Segment) vs Complete Obstructive Lesions (Fastest-Growing Segment)
The common iliac artery lesions segment held the largest share in 2026, driven by the frequent diagnosis and treatment of lesions affecting this major arterial pathway. These cases commonly require endovascular intervention to restore adequate blood flow and improve lower limb circulation, supporting sustained demand for iliac stent procedures. Established clinical treatment protocols and broad physician experience have further strengthened the segment’s leading position.
The complete obstructive lesions segment is witnessing the fastest growth in the iliac stents market as advances in interventional techniques and specialized stent technologies enable physicians to manage increasingly complex vascular occlusions. Rising awareness of minimally invasive treatment options and continuous improvements in procedural success have expanded the range of patients eligible for endovascular intervention. These developments are expected to support continued growth in the treatment of complete obstructive lesions.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | Self-expandable Stents, Balloon-expandable Stents, Covered Stents | Balloon-expandable Stents | Covered Stents |
| End-use | Hospitals, Ambulatory Surgical Centers, Others | Hospitals | Ambulatory Surgical Centers |
| Artery Lesions | Common Iliac Artery Lesions, Severe Calcified Lesions, Complete Obstructive Lesions | Common Iliac Artery Lesions | Complete Obstructive Lesions |
Competitive Landscape and Market Positioning
Major players in the iliac stents market:
- Abbott Laboratories (United States)
- Medtronic plc (Ireland)
- Boston Scientific Corporation (United States)
- Becton Dickinson and Company (United States)
- B. Braun Melsungen AG (Germany)
- Biotronik SE & Co. KG (Germany)
- Cook Medical LLC (United States)
- W. L. Gore & Associates, Inc. (United States)
- Cordis (United States)
- iVascular S.L.U. (Spain)
Clinical performance has become the central battleground in the iliac stents market, with manufacturers directing investment toward designs that improve vessel conformity, long-term patency, and procedural efficiency across increasingly diverse patient populations. Competitive positioning is increasingly influenced by the ability to engineer stents that accommodate complex vascular anatomies while supporting minimally invasive treatment approaches preferred by healthcare providers. Regulatory expectations and growing demand for robust clinical evidence further reinforce barriers to entry, encouraging sustained investment in product validation, manufacturing quality, and physician education. As treatment strategies continue to evolve, innovation is becoming more closely aligned with procedural outcomes than incremental device modifications.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (United States) | |||||||
| Medtronic plc (Ireland) | |||||||
| Boston Scientific Corporation (United States) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| B. Braun Melsungen AG (Germany) | |||||||
| Biotronik SE & Co. KG (Germany) | |||||||
| Cook Medical LLC (United States) | |||||||
| W. L. Gore & Associates Inc. (United States) | |||||||
| Cordis (United States) | |||||||
| iVascular S.L.U. (Spain) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Cook Medical | Jul-25 | Cook Medical launched the commercial availability of its Zenith iliac branch device in the United States following U.S. Food and Drug Administration approval. This endovascular treatment option for aortoiliac and iliac aneurysmal disease expands the company's specialized vascular intervention portfolio and strengthens its commercial positioning within the market. |
| Boston Scientific Corporation | Mar-25 | Boston Scientific Corporation received U.S. Food and Drug Administration approval for the Express LD Iliac Premounted Stent System for iliac artery applications. As a low-profile, balloon-expandable stent approved for iliac artery disease, this regulatory milestone enhances the company's product offerings and competitive footprint. |
| Becton, Dickinson and Company | Mar-24 | Becton, Dickinson and Company initiated an international clinical study evaluating the safety and effectiveness of the BD Vascular Covered Stent for peripheral arterial disease. This initiative aims to expand treatment options and strengthen the company's clinical evidence and market presence in peripheral vascular applications. |
| W.L. Gore & Associates, Inc. | Feb-24 | W.L. Gore & Associates received U.S. Food and Drug Administration approval for the Viabahn VBX stent graft. The device delivers enhanced structural strength compared to traditional bare metal stents, improving therapeutic capabilities for patients suffering from complex iliac occlusive disease. |
| Getinge AB | Oct-23 | Getinge AB initiated the commercial availability of the iCast covered stent system in the United States for treating iliac arterial occlusive disease. This commercial rollout expands the company's operational footprint and reinforces its specialized product delivery in the vascular segment. |
| iVascular | May-22 | iVascular initiated a clinical trial for its advanced iCover covered stent system. Designated for treating de novo aortoiliac lesions in patients with symptomatic lower limb arteriopathy, this trial advances the company's pipeline and technological adoption within the peripheral vascular intervention sector. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Iliac Stents Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Payer Type | Public Payers, Private Payers, Self-Pay |
| Distribution Channel | Direct Sales, Medical Device Distributors, Group Purchasing Organizations |
| Patient Disease Profile | Intermittent Claudication, Chronic Limb-Threatening Ischemia, In-Stent Restenosis, Other Peripheral Arterial Disease |
Iliac Stents Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Endovascular Treatment Adoption Pathways |
|
| Physician Procedure Preferences |
|
| Peripheral Intervention Center Readiness |
|
Need a different cut of the data?
Request Custom ResearchHow big is the iliac stents market?
How is the iliac stents industry projected to perform over the next decade?
Why is the shift toward minimally invasive vascular care accelerating iliac stent adoption?
How are advances in stent technology improving the iliac stents market?
Why do balloon-expandable stents hold the largest share of the iliac stents market?
Why are ambulatory surgical centers the fastest-growing end-use segment in the iliac stents market?
How does North America maintain leadership in the iliac stents market?
Why is Asia Pacific expected to be the fastest-growing iliac stents market?
Who are the major participants shaping the iliac stents landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Intelligence
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization